Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Babikir Kheiri, Mahmoud Barbarawi, Yazan Zayed, Michael Hicks, Mohammed Osman, Laith Rashdan, Htay Htay Kyi, Ghassan Bachuwa, Mustafa Hassan, Eric C. Stecker, Babak Nazer, Deepak L. Bhatt

Research output: Contribution to journalArticle

Abstract

BACKGROUND: In patients with an implantable cardioverter-defibrillator (ICD), shocks are associated with increased morbidity and mortality. Therefore, we conducted this study to evaluate the efficacy and safety of antiarrhythmic drugs and catheter ablation (CA) in the treatment of ventricular tachyarrhythmias (VT) in patients with an ICD. METHODS: An electronic database search for randomized controlled trials that evaluated antiarrhythmic drugs and CA in patients with ICD was conducted. The primary outcome was recurrent VT. Secondary outcomes were ICD shocks and any deaths. Bayesian and frequentist network meta-analyses were performed to calculate hazard ratios (HRs) and 95% credible intervals (CrIs)/CIs. RESULTS: Twenty-two randomized controlled trials were identified (3828 total patients; age 64.3±11.4; 79% males). The use of amiodarone was associated with a significantly reduced rate of VT recurrence compared with control (HR=0.34 [95% CrI=0.15-0.74]; absolute risk difference=-0.23 [95% CrI=-0.23 to -0.09]; number needed to treat=4). Sotalol was associated with increased risk of VT recurrence compared with amiodarone (HR=2.88 [95% CrI=1.35-6.46]). Compared with control, amiodarone (HR=0.33 [95% CrI=0.15-0.76]; absolute risk difference=-0.17 [95% CrI=-0.32 to -0.06]; number needed to treat=6) and CA (HR=0.52 [95% CrI=0.30-0.89; absolute risk difference=-0.12 [95% CrI=-0.24 to -0.03]; number needed to treat=8) were associated with significantly reduced ICD shocks. Compared with amiodarone, sotalol was associated with significantly increased ICD shocks (HR=2.70 [95% CrI=1.17-6.71]). The rate of death was not significantly different between the competing strategies. The node-splitting method showed no inconsistency. CONCLUSIONS: Among patients with an ICD, amiodarone significantly reduced VT recurrence and ICD shocks, while CA reduced ICD shocks. Sotalol significantly increased VT recurrence and ICD shocks compared with amiodarone. The long-term side effects of amiodarone and early complications of CA should be weighed carefully according to specific patient characteristics.

Original languageEnglish (US)
Pages (from-to)e007600
JournalCirculation. Arrhythmia and electrophysiology
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2019
Externally publishedYes

Fingerprint

Catheter Ablation
Implantable Defibrillators
Anti-Arrhythmia Agents
Tachycardia
Meta-Analysis
Amiodarone
Randomized Controlled Trials
Shock
Sotalol
Numbers Needed To Treat
Safety Management
Recurrence
Mortality
Databases
Morbidity
Safety

Keywords

  • amiodarone
  • catheter ablation
  • quality of life
  • secondary prevention
  • sotalol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. / Kheiri, Babikir; Barbarawi, Mahmoud; Zayed, Yazan; Hicks, Michael; Osman, Mohammed; Rashdan, Laith; Kyi, Htay Htay; Bachuwa, Ghassan; Hassan, Mustafa; Stecker, Eric C.; Nazer, Babak; Bhatt, Deepak L.

In: Circulation. Arrhythmia and electrophysiology, Vol. 12, No. 11, 01.11.2019, p. e007600.

Research output: Contribution to journalArticle

Kheiri, Babikir ; Barbarawi, Mahmoud ; Zayed, Yazan ; Hicks, Michael ; Osman, Mohammed ; Rashdan, Laith ; Kyi, Htay Htay ; Bachuwa, Ghassan ; Hassan, Mustafa ; Stecker, Eric C. ; Nazer, Babak ; Bhatt, Deepak L. / Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. In: Circulation. Arrhythmia and electrophysiology. 2019 ; Vol. 12, No. 11. pp. e007600.
@article{7fadbeeb712441229724992b8d8f5117,
title = "Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials",
abstract = "BACKGROUND: In patients with an implantable cardioverter-defibrillator (ICD), shocks are associated with increased morbidity and mortality. Therefore, we conducted this study to evaluate the efficacy and safety of antiarrhythmic drugs and catheter ablation (CA) in the treatment of ventricular tachyarrhythmias (VT) in patients with an ICD. METHODS: An electronic database search for randomized controlled trials that evaluated antiarrhythmic drugs and CA in patients with ICD was conducted. The primary outcome was recurrent VT. Secondary outcomes were ICD shocks and any deaths. Bayesian and frequentist network meta-analyses were performed to calculate hazard ratios (HRs) and 95{\%} credible intervals (CrIs)/CIs. RESULTS: Twenty-two randomized controlled trials were identified (3828 total patients; age 64.3±11.4; 79{\%} males). The use of amiodarone was associated with a significantly reduced rate of VT recurrence compared with control (HR=0.34 [95{\%} CrI=0.15-0.74]; absolute risk difference=-0.23 [95{\%} CrI=-0.23 to -0.09]; number needed to treat=4). Sotalol was associated with increased risk of VT recurrence compared with amiodarone (HR=2.88 [95{\%} CrI=1.35-6.46]). Compared with control, amiodarone (HR=0.33 [95{\%} CrI=0.15-0.76]; absolute risk difference=-0.17 [95{\%} CrI=-0.32 to -0.06]; number needed to treat=6) and CA (HR=0.52 [95{\%} CrI=0.30-0.89; absolute risk difference=-0.12 [95{\%} CrI=-0.24 to -0.03]; number needed to treat=8) were associated with significantly reduced ICD shocks. Compared with amiodarone, sotalol was associated with significantly increased ICD shocks (HR=2.70 [95{\%} CrI=1.17-6.71]). The rate of death was not significantly different between the competing strategies. The node-splitting method showed no inconsistency. CONCLUSIONS: Among patients with an ICD, amiodarone significantly reduced VT recurrence and ICD shocks, while CA reduced ICD shocks. Sotalol significantly increased VT recurrence and ICD shocks compared with amiodarone. The long-term side effects of amiodarone and early complications of CA should be weighed carefully according to specific patient characteristics.",
keywords = "amiodarone, catheter ablation, quality of life, secondary prevention, sotalol",
author = "Babikir Kheiri and Mahmoud Barbarawi and Yazan Zayed and Michael Hicks and Mohammed Osman and Laith Rashdan and Kyi, {Htay Htay} and Ghassan Bachuwa and Mustafa Hassan and Stecker, {Eric C.} and Babak Nazer and Bhatt, {Deepak L.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1161/CIRCEP.119.007600",
language = "English (US)",
volume = "12",
pages = "e007600",
journal = "Circulation: Arrhythmia and Electrophysiology",
issn = "1941-3149",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators

T2 - A Systematic Review and Meta-Analysis of Randomized Controlled Trials

AU - Kheiri, Babikir

AU - Barbarawi, Mahmoud

AU - Zayed, Yazan

AU - Hicks, Michael

AU - Osman, Mohammed

AU - Rashdan, Laith

AU - Kyi, Htay Htay

AU - Bachuwa, Ghassan

AU - Hassan, Mustafa

AU - Stecker, Eric C.

AU - Nazer, Babak

AU - Bhatt, Deepak L.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - BACKGROUND: In patients with an implantable cardioverter-defibrillator (ICD), shocks are associated with increased morbidity and mortality. Therefore, we conducted this study to evaluate the efficacy and safety of antiarrhythmic drugs and catheter ablation (CA) in the treatment of ventricular tachyarrhythmias (VT) in patients with an ICD. METHODS: An electronic database search for randomized controlled trials that evaluated antiarrhythmic drugs and CA in patients with ICD was conducted. The primary outcome was recurrent VT. Secondary outcomes were ICD shocks and any deaths. Bayesian and frequentist network meta-analyses were performed to calculate hazard ratios (HRs) and 95% credible intervals (CrIs)/CIs. RESULTS: Twenty-two randomized controlled trials were identified (3828 total patients; age 64.3±11.4; 79% males). The use of amiodarone was associated with a significantly reduced rate of VT recurrence compared with control (HR=0.34 [95% CrI=0.15-0.74]; absolute risk difference=-0.23 [95% CrI=-0.23 to -0.09]; number needed to treat=4). Sotalol was associated with increased risk of VT recurrence compared with amiodarone (HR=2.88 [95% CrI=1.35-6.46]). Compared with control, amiodarone (HR=0.33 [95% CrI=0.15-0.76]; absolute risk difference=-0.17 [95% CrI=-0.32 to -0.06]; number needed to treat=6) and CA (HR=0.52 [95% CrI=0.30-0.89; absolute risk difference=-0.12 [95% CrI=-0.24 to -0.03]; number needed to treat=8) were associated with significantly reduced ICD shocks. Compared with amiodarone, sotalol was associated with significantly increased ICD shocks (HR=2.70 [95% CrI=1.17-6.71]). The rate of death was not significantly different between the competing strategies. The node-splitting method showed no inconsistency. CONCLUSIONS: Among patients with an ICD, amiodarone significantly reduced VT recurrence and ICD shocks, while CA reduced ICD shocks. Sotalol significantly increased VT recurrence and ICD shocks compared with amiodarone. The long-term side effects of amiodarone and early complications of CA should be weighed carefully according to specific patient characteristics.

AB - BACKGROUND: In patients with an implantable cardioverter-defibrillator (ICD), shocks are associated with increased morbidity and mortality. Therefore, we conducted this study to evaluate the efficacy and safety of antiarrhythmic drugs and catheter ablation (CA) in the treatment of ventricular tachyarrhythmias (VT) in patients with an ICD. METHODS: An electronic database search for randomized controlled trials that evaluated antiarrhythmic drugs and CA in patients with ICD was conducted. The primary outcome was recurrent VT. Secondary outcomes were ICD shocks and any deaths. Bayesian and frequentist network meta-analyses were performed to calculate hazard ratios (HRs) and 95% credible intervals (CrIs)/CIs. RESULTS: Twenty-two randomized controlled trials were identified (3828 total patients; age 64.3±11.4; 79% males). The use of amiodarone was associated with a significantly reduced rate of VT recurrence compared with control (HR=0.34 [95% CrI=0.15-0.74]; absolute risk difference=-0.23 [95% CrI=-0.23 to -0.09]; number needed to treat=4). Sotalol was associated with increased risk of VT recurrence compared with amiodarone (HR=2.88 [95% CrI=1.35-6.46]). Compared with control, amiodarone (HR=0.33 [95% CrI=0.15-0.76]; absolute risk difference=-0.17 [95% CrI=-0.32 to -0.06]; number needed to treat=6) and CA (HR=0.52 [95% CrI=0.30-0.89; absolute risk difference=-0.12 [95% CrI=-0.24 to -0.03]; number needed to treat=8) were associated with significantly reduced ICD shocks. Compared with amiodarone, sotalol was associated with significantly increased ICD shocks (HR=2.70 [95% CrI=1.17-6.71]). The rate of death was not significantly different between the competing strategies. The node-splitting method showed no inconsistency. CONCLUSIONS: Among patients with an ICD, amiodarone significantly reduced VT recurrence and ICD shocks, while CA reduced ICD shocks. Sotalol significantly increased VT recurrence and ICD shocks compared with amiodarone. The long-term side effects of amiodarone and early complications of CA should be weighed carefully according to specific patient characteristics.

KW - amiodarone

KW - catheter ablation

KW - quality of life

KW - secondary prevention

KW - sotalol

UR - http://www.scopus.com/inward/record.url?scp=85074687280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074687280&partnerID=8YFLogxK

U2 - 10.1161/CIRCEP.119.007600

DO - 10.1161/CIRCEP.119.007600

M3 - Article

C2 - 31698933

AN - SCOPUS:85074687280

VL - 12

SP - e007600

JO - Circulation: Arrhythmia and Electrophysiology

JF - Circulation: Arrhythmia and Electrophysiology

SN - 1941-3149

IS - 11

ER -